

[Home](#) > [News and media](#) > [PHI circulars](#)

# PHI 46/23 Benefits for Prescribed List products undergoing a post-listing review

This circular describes the benefits for prescribed List products undergoing a post-listing review.

**Date published:** 4 July 2023

**Type:** PHI circular

**PHI circular type:** Protheses announcement

**Audience:** Health sector

Under the [Private Health Insurance Act 2007](#), private health insurers are required to pay benefits for a Prescribed List product when:

- the product is on the [Prescribed List of medical devices and human tissue products](#)
- the patient receives the product as part of hospital treatment or hospital substitute treatment
- the patient has appropriate health insurance to cover for the treatment
- a Medicare benefit is payable for a service associated with the use of the product.

If a product that is being subject to a [post-listing review process](#) meets the requirements above, insurers are still required to pay the associated benefits, until the outcome of the post-listing review is implemented. This includes benefits payable for urogynaecological mesh devices (mid-urethral slings); spinal cord stimulators; and surgical guides and biomodels.